Lexaria Bioscience Corp. - SIC # 6794 - PATENT OWNERS AND LESSORS

Ticker Exchange SIC # Website Latest Ticker
LEXX Nasdaq 6794 lexariabioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lexaria Bioscience Corp.

LEXX: Phase I Start Imminent - Dec 5th, 2024 11:15 am
BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals - Nov 30th, 2024 4:00 pm
Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Nov 28th, 2024 11:01 am
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs - Nov 26th, 2024 2:20 pm
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled - Nov 25th, 2024 2:00 pm
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study - Nov 20th, 2024 2:05 pm
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - Nov 14th, 2024 2:10 pm
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss - Nov 13th, 2024 2:20 pm
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments - Nov 7th, 2024 2:15 pm
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study - Oct 24th, 2024 1:10 pm
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study - Oct 22nd, 2024 1:20 pm
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Oct 16th, 2024 8:00 pm
Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth - Oct 16th, 2024 3:05 pm
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Oct 15th, 2024 12:25 pm
Lexaria Bioscience Launches Human Study of DehydraTECH-Processed Tirzepatide - Oct 9th, 2024 2:16 pm
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing - Oct 9th, 2024 1:05 pm
Lexaria Updates Current GLP-1 Market - Oct 8th, 2024 1:20 pm
Lexaria Appoints Michael Shankman as Chief Financial Officer - Oct 1st, 2024 1:25 pm
Lexaria Bioscience Receives Approval From Independent Review Board for Pilot Study of Tirzepatide - Sep 27th, 2024 2:54 pm
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 - Sep 27th, 2024 1:20 pm